Cethromycin
OBJECTIVE To review the pharmacology, chemistry, microbiology, in vitro susceptibility, mechanism of resistance, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, drug interactions, dosage, and administration of cethromycin, a new ketolide antibiotic. DATA SOURCES Literature was obtaine...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , |
| التنسيق: | article |
| منشور في: |
2013
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/4458 http://dx.doi.org/10.1345/aph.1R435 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://journals.sagepub.com/doi/full/10.1345/aph.1R435 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513463630430208 |
|---|---|
| author | Mansour, Hanine |
| author2 | Chahine, Elias B. Karaoui, Lamis R. El-Lababidi, Rania M. |
| author2_role | author author author |
| author_facet | Mansour, Hanine Chahine, Elias B. Karaoui, Lamis R. El-Lababidi, Rania M. |
| author_role | author |
| dc.creator.none.fl_str_mv | Mansour, Hanine Chahine, Elias B. Karaoui, Lamis R. El-Lababidi, Rania M. |
| dc.date.none.fl_str_mv | 2013 2016-09-29T13:12:42Z 2016-09-29T13:12:42Z 2016-09-29 |
| dc.identifier.none.fl_str_mv | 1060-0280 http://hdl.handle.net/10725/4458 http://dx.doi.org/10.1345/aph.1R435 Mansour, H., Chahine, E. B., Karaoui, L. R., & El-Lababidi, R. M. (2013). Cethromycin: a new ketolide antibiotic. Annals of Pharmacotherapy, 47(3), 368-379. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://journals.sagepub.com/doi/full/10.1345/aph.1R435 |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | Annals of Pharmacotherapy |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Cethromycin A New Ketolide Antibiotic |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | OBJECTIVE To review the pharmacology, chemistry, microbiology, in vitro susceptibility, mechanism of resistance, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, drug interactions, dosage, and administration of cethromycin, a new ketolide antibiotic. DATA SOURCES Literature was obtained through searching PubMed (1950-October 2012), International Pharmaceutical Abstracts (1970-October 2012), and a bibliographic review of published articles. Search terms included cethromycin, ABT-773, ketolide antibiotic, and community-acquired pneumonia. STUDY SELECTION AND DATA EXTRACTION All available in vitro and preclinical studies, as well as Phase 1, 2, and 3 clinical studies published in English were evaluated to summarize the pharmacology, chemistry, microbiology, efficacy, and safety of cethromycin in the treatment of respiratory tract infections. DATA SYNTHESIS Cethromycin, a new ketolide, has a similar mechanism of action to telithromycin with an apparently better safety profile. Cethromycin displays in vitro activity against selected gram-positive, gram-negative, and atypical bacteria. The proposed indication of cethromycin is treatment of mild to moderate community-acquired bacterial pneumonia in patients aged 18 years or older. Based on clinical studies, the recommended dose is 300 mg orally once a day without regard to meals. Cethromycin has an orphan drug designation for tularemia, plague, and anthrax prophylaxis. The Food and Drug Administration denied approval for the treatment of community-acquired pneumonia in 2009; a recent noninferiority trial showed comparable efficacy between cethromycin and clarithromycin. Preliminary data on adverse effects suggest that cethromycin is safe and gastrointestinal adverse effects appear to be dose-related. CONCLUSIONS Cethromycin appears to be a promising ketolide for the treatment of mild to moderate community-acquired pneumonia. It was denied approval by the FDA in 2009 pending more evidence to show its efficacy, with more recent studies showing its noninferiority to antibiotics for the same indication. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_2fa7acb30a1cb5a477bdac60e2d62bf7 |
| identifier_str_mv | 1060-0280 Mansour, H., Chahine, E. B., Karaoui, L. R., & El-Lababidi, R. M. (2013). Cethromycin: a new ketolide antibiotic. Annals of Pharmacotherapy, 47(3), 368-379. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/4458 |
| publishDate | 2013 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | CethromycinA New Ketolide AntibioticMansour, HanineChahine, Elias B.Karaoui, Lamis R.El-Lababidi, Rania M.OBJECTIVE To review the pharmacology, chemistry, microbiology, in vitro susceptibility, mechanism of resistance, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, drug interactions, dosage, and administration of cethromycin, a new ketolide antibiotic. DATA SOURCES Literature was obtained through searching PubMed (1950-October 2012), International Pharmaceutical Abstracts (1970-October 2012), and a bibliographic review of published articles. Search terms included cethromycin, ABT-773, ketolide antibiotic, and community-acquired pneumonia. STUDY SELECTION AND DATA EXTRACTION All available in vitro and preclinical studies, as well as Phase 1, 2, and 3 clinical studies published in English were evaluated to summarize the pharmacology, chemistry, microbiology, efficacy, and safety of cethromycin in the treatment of respiratory tract infections. DATA SYNTHESIS Cethromycin, a new ketolide, has a similar mechanism of action to telithromycin with an apparently better safety profile. Cethromycin displays in vitro activity against selected gram-positive, gram-negative, and atypical bacteria. The proposed indication of cethromycin is treatment of mild to moderate community-acquired bacterial pneumonia in patients aged 18 years or older. Based on clinical studies, the recommended dose is 300 mg orally once a day without regard to meals. Cethromycin has an orphan drug designation for tularemia, plague, and anthrax prophylaxis. The Food and Drug Administration denied approval for the treatment of community-acquired pneumonia in 2009; a recent noninferiority trial showed comparable efficacy between cethromycin and clarithromycin. Preliminary data on adverse effects suggest that cethromycin is safe and gastrointestinal adverse effects appear to be dose-related. CONCLUSIONS Cethromycin appears to be a promising ketolide for the treatment of mild to moderate community-acquired pneumonia. It was denied approval by the FDA in 2009 pending more evidence to show its efficacy, with more recent studies showing its noninferiority to antibiotics for the same indication.PublishedN/A2016-09-29T13:12:42Z2016-09-29T13:12:42Z20132016-09-29Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1060-0280http://hdl.handle.net/10725/4458http://dx.doi.org/10.1345/aph.1R435Mansour, H., Chahine, E. B., Karaoui, L. R., & El-Lababidi, R. M. (2013). Cethromycin: a new ketolide antibiotic. Annals of Pharmacotherapy, 47(3), 368-379.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://journals.sagepub.com/doi/full/10.1345/aph.1R435enAnnals of Pharmacotherapyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/44582022-03-22T14:25:42Z |
| spellingShingle | Cethromycin Mansour, Hanine |
| status_str | publishedVersion |
| title | Cethromycin |
| title_full | Cethromycin |
| title_fullStr | Cethromycin |
| title_full_unstemmed | Cethromycin |
| title_short | Cethromycin |
| title_sort | Cethromycin |
| url | http://hdl.handle.net/10725/4458 http://dx.doi.org/10.1345/aph.1R435 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://journals.sagepub.com/doi/full/10.1345/aph.1R435 |